News

A prospective study reports an association between diabetes mellitus and anuria with high post-void residual post-transplantation.

Wingate reviews new Crohn’s and Colitis Foundation data on insurance barriers faced by young adults with IBD and offers practical insights for overcoming these challenges.

Topline 52 week results show durable growth without compromising safety or tolerability, as well as benefits beyond linear growth with combination treatment.

Rubin discusses the recently released best practice recommendations for HypoPT treatment, explaining how clinicians can help turn this dangerous disease around.

According to new research, investigators project a rising chronic kidney disease burden in young adults and a declining incidence in children by 2050.

In this post hoc analysis, investigators used phase 3 data on vunakizumab to investigate the impact of early response on long-term efficacy in those with psoriasis.

A study found tahini was associated with lower reaction thresholds and higher anaphylaxis rates than whole seeds, suggesting it may better reflect true sesame allergy risk.

The Q4 recap for cardiology spotlights major FDA decisions, key clinical trial updates, and more.

December 2025 saw new data on asthma therapies and new insights from experts on continuing trends in the field.

The document outlines 14 best-practice advice statements for diagnosing and managing refractory constipation, with an emphasis on surgical intervention.

A study links caregiver beliefs, mental health challenges, multiple allergens, and prior anaphylaxis to worse food allergy–related quality of life in pediatric patients.

Jasper Therapeutics has released new, positive findings on the use of briquilimab, a novel antibody therapy targeting KIT (CD117), in patients with CSU.

Rubin discusses an analysis of Ascendis’s program for patients who had received PTH treatment but weren’t eligible for clinical trials of palopegteriparatide.

A trio of professional societies voice concerns about certain elements of the Dietary Guidelines for Americans, 2025–2030, and their potential negative health impacts.

The FDA has not approved the sNDA for tasimelteon in jet lag disorder in its current form, citing positive efficacy but limited real-world applicability.

Clinically meaningful improvements in global IBS symptom severity were observed as early as week 1 and sustained through week 7.

This study evaluated the drug survival of different biologic therapies for patients with psoriasis in a routine clinical practice setting.

The Q4 recap for gastroenterology spotlights GI FDA news, new AGA guidelines, trial data for UC therapies, and more.

Meta-analysis shows exercise may match therapy in improving depressive symptoms, with moderate-intensity and 13–36 sessions offering the greatest benefit.

Osborne discusses the background behind fenofibrates’ approval for cardiovascular event reduction, despite no evidence supporting their efficacy.

Investigators look at the ways in which CSU impacts family members supporting those with CSU, using the Family Dermatology Life Quality Index (FDLQI).

Quarter 4 2025 showed robust advancements in the nephrology field, including FDA news, trial updates, and featured content.

A study found that low-intensity transcranial ultrasound stimulation targeting the left dlPFC improves depression while avoiding common side effects associated with TMS and tDCS.

Pulmonary arterial hypertension treatment continues to evolve with new therapies and strategies.

Study findings highlight the importance of etiology-based chronic pancreatitis management, with NARCP linked to worse mortality, EPI, and other clinical outcomes.

The Q4 recap for endocrinology spotlights major FDA decisions, updates to diabetes care standards, and key clinical trial updates.

An age-based observational study in glomerular disease suggests different rates of disease progression and remission in young adults compared to adult and pediatric patients.

The Q4 recap for pulmonology spotlights regulatory and clinical advances across asthma and pulmonary fibrosis.